Objectives: To assess the detection rate of putative Lynch syndrome-associated upper urinary tract urothelial cancer among all upper urinary tract urothelial cancers and to examine its clinicopathological characteristics. Methods: A total of 143 patients with upper urinary tract urothelial cancer who had received total nephroureterectomy were immunohistochemically stained for the expression of mismatch repair proteins MLH1, PMS2, MSH2 and MSH6. For all suspected mismatch repair-deficient cases, MMR genetic testing was recommended and clinicopathological features were examined. Results: Loss of mismatch repair proteins was found in seven patients (5%) who were thus categorized as putative Lynch syndrome-associated upper urinary tract urothelial cancer. Five of these patients showed dual loss of MSH2/MSH6. Two patients were confirmed to be MSH2 germline mutation carriers. Histologically, all seven tumors were low-grade atypical urothelial carcinoma and showed its unique histological features, such as an inverted papilloma-like growth pattern and a villous to papillary structure with mild stratification of tumor cells. Six tumors had no invasion of the muscularis propria. No recurrence or cancer-related deaths were reported in these seven patients. Just three patients met the revised Amsterdam criteria. Conclusions: This is the first report that universally examined mismatch repair immunohistochemical screening for upper urinary tract urothelial cancers. The prevalence (5%) of putative Lynch syndrome-associated upper urinary tract urothelial cancers is much higher than we had expected. We ascertained that putative Lynch syndrome-associated upper urinary tract urothelial cancers were clinically in the early stage and histologically classified into low-grade malignancy with its characteristic pathological features. The clinicopathological characteristics that we found in the present study could become additional possible markers in the diagnosis of Lynch syndromeassociated upper urinary tract urothelial cancers.
Introduction
LS is an autosomal dominant inherited cancer syndrome caused by germline mutations in DNA MMR genes including MLH1, MSH2, MSH6 and PMS2.
1 Mutations in the MMR gene occur in 0.2% of the general population. 2, 3 Their inactivation results in a large increase in spontaneous mutability and a direct cellular oncogenic effect. 1 LS carriers are thus prone to various malignancies including cancers of the colon, rectum, endometrium, ureter, renal pelvis and small bowel. LS has also been referred to as HNPCC syndrome. 4 Many detailed epidemiological studies have reported on HNPCC. 5, 6 HNPCC develops with early onset and involves multiple cancers. The lifetime risk of colorectal cancers in patients with LS is thought to exceed 50%. 7 Furthermore, it has been reported that approximately 1-5% of all colorectal cancers are caused by LS. 8, 9 In addition, LS-related colorectal cancers have unusual pathological characteristics, including tumor infiltrating lymphocytes, Crohn's-like lymphocytic reaction, mucinous/signet-ring differentiation or medullary growth pattern. 5 Revised Bethesda guidelines using characteristic histology in LSrelated colorectal cancers were developed to help doctors identify patients for whom MSI testing or IHC testing of MMR proteins is warranted to evaluate LS. 10 UUTC is the third most frequent cancer in LS. 11 However, LS is not well known among urologists, and LS-associated UUTC is clearly underestimated in clinical practice. The assessment of the prevalence of putative LS-associated UUTCs among all UUTCs has been studied by MSI detection for more than a decade. 11 However, the exact prevalence of putative LS-associated UUTCs among all UUTCs has not been clarified due to variability in patient screening and inadequate evaluation of patients at risk, and no characteristic clinicopathological features of putative LS-associated UUTCs have been identified. 11 As a result, it is presumed that LSassociated UUTC is often misclassified as sporadic. Therefore, identification of the clinicopathological features will make it easier to distinguish putative LS-associated UUTCs from sporadic UUTCs. Differential diagnosis in such cases is important, as suspected LS patients and their families will benefit from lifesaving intensive cancer surveillance. Here, we estimate the prevalence of putative LS-associated UUTCs through universal IHC screening of MMR proteins for all UUTCs, and examine the clinicopathological characteristics of these cases in order to enlighten urologists on putative LSassociated UUTCs.
Methods
In total, 143 serial patients with pathological UUTC who underwent total nephroureterectomy in Toranomon Hospital, Tokyo, Japan, between January 2003 and December 2014 were identified from the files of the contributing departments of pathology. The institutional review board of Toranomon Hospital approved this study. After the institutional review board approval, the data were retrospectively obtained from medical charts (including past history and family history), operative notes, pathology reports and radiographic imaging findings. Formalin-fixed, paraffin-embedded tissue samples were available for histological re-evaluation. Tumor stage was determined according to the American Joint Cancer Committee/Union Internationale Contre le Cancer staging system, and the grade was determined according to the World Health Organization 2004 grading system. The Revised Amsterdam criteria were retrospectively applied to these patients.
The surgical specimens of all patients with UUTCs who had given their consent for their specimens to be used for research, independent of clinical criteria, were retrospectively tested immunohistochemically for the expression of the MMR proteins MLH1, PMS2, MSH2 and MSH6. To achieve high standardization in IHC analysis, we constructed a tumor and control tissue microarray from tissue cores (3-lm sections, 3 mm in diameter) of each paraffin-embedded block. We used the standard avidin-biotin-peroxidase complex method with an automated immunostainer (BenchMark XT; Ventana Medical Systems, Tucson, AZ, USA), independent of clinical criteria. The antibodies applied were MLH1 (M3640; DAKO, Glostrup, Denmark; dilution 1:50), MSH2 (#2017; Cell Signaling Technology Japan, Tokyo, Japan; dilution 1:200), MSH6 (M3646; DAKO; dilution 1:50) and PMS2 (M3647; DAKO; dilution 1:40). The slides were evaluated by two urological pathologists (NI and YM) who were blinded to the clinical data. IHC expression of MMR proteins was scored as negative or positive. If the tumor showed complete absence or nuclear expression in <5% of tumor cells in at least one MMR, but retained expression in inflammatory cells and/or adjacent normal tissue as positive controls, the case was strictly considered MMR-deficient and scored as negative. We refer herein to MMR-IHC deficient UUTCs as LS-associated UUTCs regardless of genetic testing results. Cases with either strong (>30%) or weak (<30% but >5%) nuclear positive reaction were strictly scored as positive. The hematoxylin-eosin-stained slides were independently reviewed by the same two urological pathologists. Distinctive pathological features including growth architecture of MMRdeficient patients were also assessed.
In all patients suspected of MMR deficiency based on IHC, genetic counseling for LS at a collaborating institution was recommended. In these counseling sessions, a medical doctor explained LS and the significance of the genetic tests. If clients wanted to receive genetic tests, germline genetic tests focusing on MMR genes were carried out.
Genetic mutation was analyzed by two methods: polymerase chain reaction direct sequence and MLPA. Polymerase chain reaction direct sequence was outsourced to FALCO (Kyoto, Japan). DNA from probands was extracted from blood lymphocytes. If necessary, we confirmed alterations of MLH1, PMS2, MSH2 and MSH6 by direct exon-byexon sequencing of genomic DNA on an ABI 377 DNA Sequencer (Applied Biosystems, Foster City, CA, USA) at the laboratory of the Cancer Institute Hospital. To detect genomic rearrangements, MLPA analysis was carried out at the Cancer Institute Hospital laboratory with the kit P003-D1 for MSH2 and MLH1 (MRC-Holland, Amsterdam, the Netherlands). All steps were carried out according to the manufacturer's instructions. Products were separated by CEQ-8000 capillary electrophoresis (SCIEX, Framingham, MA, USA).
Results
A total of 143 cases with UUTC were identified. Detailed clinicopathological characteristics regarding age, sex, tumor grade and tumor stage are summarized in Table 1 . The median age of all patients at the time of surgery was 70 years (range 45-92 years). There were 101 male patients (71%) and 42 female patients (29%). The primary cancer site was the urinary bladder in 71 patients (50%) and the ureter in 72 (50%). A total of 54 patients (38%) had locally advanced disease (cT3 or T4) in the primary site.
Loss of expression (immunonegative) in at least one of the four MMR proteins occurred in seven of 143 patients (5%). The distribution of loss of expression of the MMR proteins in these seven patients was as follows: combined MLH1/PMS2 loss in one case, combined MSH2/MSH6 loss ( Fig. 1a-d) in five cases and isolated MSH6 loss in one case.
These seven patients were advised to undergo genetic counseling and testing, but five of them declined. Just two patients with MSH2/MSH6 loss were genetically tested, and both were diagnosed as MSH2 germline mutation carriers (Table 2) . One showed deletion of exons 1-6 in the MSH2 gene by the MLPA method, and the other showed a single nucleotide mutation from A to G at the splice acceptor site of intron 13 in the MSH2 gene. Detailed information regarding these seven MMR-deficient patients is found in Table 2 .
Five patients were female and two were male. The median age was 71 years (range 51-77) at the time of UUTC diagnosis, similar to that of MMR-positive sporadic UUTC patients. Only one patient was relatively young, at 51 years-of-age. Ureteral cancer was present in five patients, and renal pelvic cancer was present in two. In terms of laterality, four were left and three were right. One patient was a current smoker (case 7 in Table 2 ), two patients were former smokers (case 2 and 4 in Table 2 ) and four were never-smokers. There were no bilateral UUTC cases in the present study. All seven showed low-grade tumors. Only one patient had muscle-invasive disease, whereas three had pT1 disease and three had pTa. At the median follow up of 51 months, no urothelial cancer-related recurrence or deaths were reported in these seven patients.
Of these seven MMR-deficient patients, just three (42%) matched the revised Amsterdam criteria, and two of these three showed MSH2 germline mutation. In contrast, no MMR-positive patients were incompatible with the revised Amsterdam criteria. Just two of the seven MMR-deficient patients had a previous history of primary colorectal cancer and matched the revised Bethesda guidelines. One of these two showed an MSH2 germline mutation. However, one of the two LS patients with a germline mutation did not match the revised Bethesda guidelines at the time of UUTC diagnosis, because she had developed metachronous LS-associated cancers (endometrial and gastric cancer) after the initial diagnosis of UUTC.
The histological characteristics of putative LS-associated UUTCs were very unique. Six cases showed an inverted papilloma-like growth pattern that mainly consisted of inside growth and mild exophytic growth with exposure to lumen, and were partly covered by urothelial epithelia without atypia (Fig. 2a,b) , defined as an inverted growth pattern. Just 13 patients (9%) of all 143 cases with UUTC showed an inverted papilloma-like growth pattern. Four cases had villous-to-papillary structures with mild stratification of tumor cells (Fig. 2c,d ), defined as a villous growth pattern. All cases consisted of tumor cells with low-grade nuclear atypia without irregular cell arrangement. Histological features typical of LS-associated colorectal cancer, including solid growth, increased cytological atypia and increased numbers of intratumoral lymphocytes, were not observed in putative LS-associated UUTCs.
Discussion
Recent guidelines strongly recommend universal LS screening for all patients with colorectal cancer, regardless of clinicopathological features or family history, enabling LS patients to receive life-saving intensive cancer surveillance. 12 MMR-IHC is now becoming the preferred first-line screening test for LS-related cancer at many institutions because of its relative ease and ability to target confirmatory germline sequencing, as well as its greater affordability, sensitivity, cost-effectiveness and feasibility compared with MSI testing. 13 , 14 As we do not know the exact prevalence of putative LS-associated UUTC, we carried out MMR-IHC as a form of universal screening in all patients with UUTC in order to estimate the prevalence of putative LS-associated UUTC and to examine its clinicopathological characteristics. 11, 14 In the present study, approximately 5% of all UUTCs could be diagnosed as putative LS-associated UUTCs with loss of MMR proteins. The prevalence of MMR protein loss (5%) was thus much higher in UUTC patients than in the general population (0.2%), 2, 3 and similar to that of colorectal and endometrial carcinoma. 8, 9, 15 Therefore, putative LS-associated UUTCs might be much more common than expected. In fact, a recent study has also reported that loss of MMR proteins was identified in 7% of all UUTCs.
14 The present study also showed combined MSH2/MSH6 loss in five patients. It is well known that the risk of UUTC is greater in individuals with MSH2/MSH6 loss (especially MSH2 germline mutations) than in those with other forms of MMR loss, which coincided perfectly with the present results. 14, 16 The average age for LS-associated colorectal cancer is 45 years, or roughly 20-30 years younger than the average age of 72 years for colorectal cancer in the general population. 5 In contrast, a recent case-controlled study showed that patients with LS are diagnosed with UUTC several years younger than patients with sporadic onset are. 14, 17, 18 It has been shown that LS patients develop UUTC approximately 15 years after developing other prior LS-related forms of cancer. 19 In the present study, the median age at diagnosis for LS-associated UUTC was 71 years compared with 70 years in the general UUTC population. Therefore, LS-associated UUTC might be more likely to be diagnosed at a relatively older age compared with that of LS-related colorectal cancer because of its low malignant potential. In addition, five of the seven suspected LS-associated UUTC patients in the present study were female. Patients with putative LS-associated UUTC are more likely to be female compared with patients with sporadic UUTC. 5, 16 The LS-associated UUTC group has also been reported to have a higher proportion of ureteral cancer. 17, 18 The present study also showed that ureteral cancer was present in five of the seven patients. In this study, three patients were smokers. Smoking is well known to be associated with urothelial cancer occurrence in the general population. In addition, a previous retrospective cohort study showed that smoking was associated with increased risk of colorectal cancers in LS because of epigenetic modification of the MLH1 and MSH2 gene as a second hit in LS. 20 Therefore, smoking might be more strongly associated with UUTCs in patients with LS than in the general population.
Pathologically, all seven of our LS-associated UUTCs had low-grade urothelial carcinoma showing non-muscle-invasive behavior in the pT category. No urothelial cancer-related recurrence or deaths occurred. In fact, low-grade disease has been reported to be more frequent in hereditary UUTCs than in sporadic UUTCs. 21 In contrast, there is another recent report that all UUTCs in patients with LS showed high-grade morpholology, but these lacked significant pleomorphism and had pushing rather than destructive infiltrative growth.
14 Therefore, its reproducible morphological tumor grade should be defined by further additional studies. In addition, the survival rate is also significantly better in patients with hereditary-like UUTCs than in those with sporadic UUTCs. 22 Interestingly, patients with LS-related colorectal cancer have also been reported to show superior overall survival compared with those with sporadic colorectal cancer, even when controlled for stage and age. 23 Therefore, low malignant potential might be characteristic of LS-associated UUTC, as it is of LS-associated colorectal cancer. Although we experienced no bilateral UUTCs, a recent retrospective study reported a potentially increased risk of bilaterality. 24 It is important to detect LS-associated UUTC early and to survey the development of metachronous UUTC on the contralateral side. Considering these clinicopathological characteristics of LS-associated UUTC, renal preservation involving ureteroscopic laser ablation might be a better option than nephroureterectomy.
The present study had an important limitation: we could not carry out genetic testing to enable definitive diagnosis in all patients with loss of MMR-IHC expression. As this limitation makes our conclusions weak, thoughtful interpretation and consideration of our data is required. MLH1/PMS2 protein loss is often caused by the hypermethylation of the MLH1 promoter region in elderly patients with colorectal cancer, which was not known in LS-associated UUTCs. 24 In one case with dual MLH1/PMS2 protein loss, we could not carry out genetic testing or BRAFV600E mutational status testing to examine hypermethylation of the MLH1 promoter region. 25 This case involved an elderly patient with late-onset UUTC who had no previous or family history of cancer. Therefore, his case might have arisen from sporadic hypermethylation in the MLH1 promoter region. In addition, a recent review of the relevant literature has shown an increased incidence of non-methylated and MMR-deficient cancers that show no discernible mutations, with some studies suggesting >50% discordance rates between MMR protein loss and the absence of germline mutations. 13, 26 One of the explanations for the discordance between MMR protein loss and the absence of germline mutations might be biallelic somatic mutation. 26 Therefore, in the present study, we estimated the prevalence of putative LS-associated UUTCs, despite the lack of genetic testing of all UUTCs, using universal MMR-IHC with a strict negative criterion (negative: complete absence or nuclear expression in <5%) to prevent false positive IHC results.
In the present study, just three of the seven MMR-deficient patients (42%) matched the revised Amsterdam criteria. In other words, screening algorithms based on the revised Amsterdam criteria including age and personal/family cancer history would have failed to identify a significant proportion of LS-associated UUTCs. In fact, 2.7% have been reported to show loss of MMR proteins in patients without a history of LS-associated cancers.
14 In addition, just 41% of LS-related colorectal cancers with MMR gene mutations met the revised Amsterdam criteria. 27 Therefore, in the future, universal systematic tumor screening using MMR-IHC might be required in UUTCs as well as in colorectal cancers or endometrial cancers.
Putative LS-associated UUTCs showed a characteristic pathological histology consisting of low-grade urothelial carcinoma with an inverted growth pattern and/or a villous-to-papillary growth pattern. In another study, an exophytic or inverted growth pattern in UUTC was thought to be associated with high MSI. 28 Therefore, this characteristic pathology might serve as a possible marker lesion in the diagnosis of LS-associated UUTCs. This will require additional verification. In addition, there are a few reports suggesting that bladder cancer is one of the LS-associated cancers. 29 Unlike UUTC, however, the details of bladder cancer in LS have been less thoroughly investigated. Therefore, no difference in the clinicopathological background between UUTC and bladder cancer has been identified to date. In future, we will study the clinicopathological characteristics of bladder cancer in LS.
The present findings can help to improve the diagnosis of putative LS-associated UUTC from clinicopathological findings in ordinary clinical practice, which will be helpful for treatment selection and the establishment of surveillance in LS-relevant cancers in order to prolong overall survival and increase quality of life in LS patients.
